Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.59 |
| ▸ | GSR | P00390 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249147 | 1.00 | CPB2 (0.59) | CPB2GSRCYP1A2GNAI3GNAO1 | |
| SCHEMBL11511459 | 1.00 | CPB2 (0.59) | CPB2GSRCYP1A2GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL213478 | 0.98 | CPB2 (0.57) | CPB2GSRCYP1A2GNAI3GNAO1 | |
| Ammonia Solution, Strong SCHEMBL21802416 | 0.98 | CPB2 (0.57) | CPB2GSRCYP1A2GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL3395631 | 0.98 | CPB2 (0.57) | CPB2GSRCYP1A2GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL213479 | 0.98 | CPB2 (0.57) | CPB2GSRCYP1A2GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL2497633 | 0.98 | CPB2 (0.57) | CPB2GSRCYP1A2GNAI3GNAO1 | |
| SCHEMBL28597390 | 0.98 | CPB2 (0.62) | CPB2GSRCYP1A2GNAI3GNAO1 | |
| Ammonia Solution, Strong SCHEMBL28880801 | 0.98 | CPB2 (0.57) | CPB2GSRCYP1A2GNAI3GNAO1 | |
| Ethylenediamine SCHEMBL28433198 | 0.96 | CPB2 (0.56) | CPB2GSRCYP1A2GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630661-B2 | Additives useful in 3D printing technologies | Evonik Operations GmbII (DE) | 2026-05-19 | — | — | US | claimed |
| US-12616948-B2 | Polyamide microcapsules | FIRMENICH SA (CH) | 2026-05-05 | — | — | US | claimed |
| US-12599699-B2 | Co-crosslinked hyaluronic acid-silk fibroin hydrogels for improving tissue graft viability and for soft tissue augmentation | ALLERGAN, INC. (US) | 2026-04-14 | — | — | US | claimed |
| EP-4720322-A2 | ENZYME-CATALYZED REGIOSELECTIVE POLYMERIZATION FOR PREPARATION OF LINEAR POLYLYSINE OR POLYARGININE | BASF SE (DE) | 2026-04-08 | — | — | EP | claimed |
| EP-4496840-B1 | SURFACE ACTIVATION OF SILICONE | HASKOLI ISLANDS (IS) | 2026-02-04 | — | — | EP | claimed |
| EP-4673426-A1 | FUNCTIONALIZED BIODEGRADABLE SURFACTANTS AND METHODS USE | Locus Solutions IPCO, LLC (US) | 2026-01-07 | — | — | EP | claimed |
| US-12508565-B2 | Polyamide microcapsules | FIRMENICH SA (CH) | 2025-12-30 | — | — | US | claimed |
| US-12365853-B2 | Cleavable multi-alcohol-based microcapsules | FIRMENICH SA (CH) | 2025-07-22 | — | — | US | claimed |
| US-20250215175-A1 | SURFACE ACTIVATION OF SILICONE | HASKOLI ISLANDS (IS) | 2025-07-03 | — | — | US | claimed |
| CN-120115098-A | Method for producing polyamide microcapsules | 弗门尼舍有限公司 | 2025-06-10 | — | — | CN | claimed |
| EP-1156812-A1 | MULTIPARTICULATE FORMULATION | ISIS PHARMACEUTICALS, INC. (US) | 2001-11-28 | — | — | EP | claimed |
| WO-2001065935-A1 | KIDNEY PERFUSION SOLUTION CONTAINING NITRIC OXIDE DONOR | VODOVOTZ YORAM (US) | 2001-09-13 | — | — | WO | claimed |
| WO-2000050050-A1 | MULTIPARTICULATE FORMULATION | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-31 | — | — | WO | claimed |
| EP-0555229-B1 | ACCUMULATION OF AMINO ACIDS AND PEPTIDES INTO LIPOSOMES | LIPOSOME CO INC (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0555229-A1 | ACCUMULATION OF AMINO ACIDS AND PEPTIDES INTO LIPOSOMES. | LIPOSOME CO INC (US) | 1993-08-18 | — | — | EP | claimed |
| EP-0555229-A4 | ACCUMULATION OF AMINO ACIDS AND PEPTIDES INTO LIPOSOMES. | LIPOSOME CO INC (US) | 1993-06-16 | — | — | EP | claimed |
| WO-1992002244-A1 | ACCUMULATION OF AMINO ACIDS AND PEPTIDES INTO LIPOSOMES | THE LIPOSOME COMPANY, INC. (US) | 1992-02-20 | — | — | WO | claimed |
| US-4940662-A | Low-molecular weight peptide mixture and method of producing same | TERUMO KABUSHIKI KAISHA (JP) | 1990-07-10 | — | — | US | claimed |
| US-4518691-A | In vitro enzymatic process for preparing glucuronides of ester-containing anticholinergics | REPLIGEN CORPORATION (US) | 1985-05-21 | — | — | US | claimed |
| US-4169207-A | HEATING THE DIHYDROCHLORIDE SALT UNDER ANHYDROUS CONDITIONS IN AN HYDROGEN ATMOSPHERE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1979-09-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599699-B2 | Co-crosslinked hyaluronic acid-silk fibroin hydrogels for improving tissue graft viability and for soft tissue augmentation | CD44, FIBP, FABP4 | CPB2 3519/4885GSR 2334/4885CYP1A2 4386/4885 |
| US-12508565-B2 | Polyamide microcapsules | PHGDH, GLUL, PCCA | CPB2 641/4885GSR 2141/4885CYP1A2 4440/4885 |
| US-12630661-B2 | Additives useful in 3D printing technologies | HTR3D, HTR3B, HTR3C | CPB2 3116/4885GSR 4390/4885CYP1A2 1419/4885 |
| US-12616948-B2 | Polyamide microcapsules | HDHD5, DDC, USP39 | CPB2 1029/4885GSR 3984/4885CYP1A2 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.